Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA, Bergmeijer TO, Tantry US, ten Berg JM, Angiolillo DJ, James S, Lindahl TL, Svensson P, Jakubowski JA, Brown PB, Duvvuru S, Sundseth S, Walker JR, Small D, Moser BA, Winters KJ, Erlinge D. Gurbel PA, et al. Among authors: winters kj. Thromb Haemost. 2014 Sep 2;112(3):589-97. doi: 10.1160/TH13-10-0891. Epub 2014 Jul 10. Thromb Haemost. 2014. PMID: 25008027 Free article. Clinical Trial.
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C. Braun OÖ, et al. Among authors: winters kj. Thromb Haemost. 2013 Dec;110(6):1223-31. doi: 10.1160/TH13-03-0263. Epub 2013 Sep 5. Thromb Haemost. 2013. PMID: 24009042 Clinical Trial.
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
Erlinge D, James S, Duvvuru S, Jakubowski JA, Wagner H, Varenhorst C, Tantry US, Brown PB, Small D, Moser BA, Sundseth SS, Walker JR, Winters KJ, Gurbel PA. Erlinge D, et al. Among authors: winters kj. Thromb Haemost. 2014 May 5;111(5):943-50. doi: 10.1160/TH13-09-0767. Epub 2014 Jan 9. Thromb Haemost. 2014. PMID: 24402637 Clinical Trial.
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. Jakubowski JA, et al. Among authors: winters kj. Am J Cardiovasc Drugs. 2017 Apr;17(2):109-121. doi: 10.1007/s40256-016-0202-3. Am J Cardiovasc Drugs. 2017. PMID: 27854064 Review.
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD. Frelinger AL 3rd, et al. Among authors: winters kj. J Thromb Haemost. 2008 Feb;6(2):359-65. doi: 10.1111/j.1538-7836.2008.02838.x. Epub 2007 Nov 15. J Thromb Haemost. 2008. PMID: 18021304 Free article.
106 results